Randomised clinical trial: a placebo‐controlled study of intravenous golimumab induction therapy for ulcerative colitis
P. Rutgeerts, Omoniyi J. Adedokun(Western University), Walter Reinisch(Medical University of Vienna), William J. Sandborn(University of San Diego), Peter G. Gibson(University Gastroenterology), H. Zhang(Janssen (United States)), Brian G. Feagan(Western University), Colleen Marano(Johnson & Johnson (United States)), Lakshmi Padgett(Janssen (United States)), Cynthia Guzzo(Janssen (Belgium)), J.‐F. COLOMBEL(Hôpital Claude Huriez), Richard Strauß(Hennepin County Medical Center), Jewel Johanns(Johnson & Johnson (United States))
Cited by 86
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Crohn's disease
|The Lancet|2012|2.1k